GC Cell (A144510) 주식 개요GC녹십자는 세포치료제를 개발하는 회사입니다. 자세히 보기A144510 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성4/6배당0/6위험 분석지난 5년간 매년 수익이 79.4% 감소했습니다.모든 위험 점검 보기A144510 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩20.55k55.8% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-273b236b2016201920222025202620282031Revenue ₩206.8bEarnings ₩37.6bAdvancedSet Fair ValueView all narrativesGC Cell Corporation 경쟁사Dx & VxSymbol: KOSDAQ:A180400Market cap: ₩316.4bAnterogen.Co.LtdSymbol: KOSDAQ:A065660Market cap: ₩304.2bEuBiologicsSymbol: KOSDAQ:A206650Market cap: ₩396.2bHEM PharmaSymbol: KOSDAQ:A376270Market cap: ₩418.4b가격 이력 및 성과GC Cell 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩20,550.0052주 최고가₩28,450.0052주 최저가₩18,210.00베타0.641개월 변동-18.77%3개월 변동-19.09%1년 변동1.23%3년 변동-54.84%5년 변동-78.75%IPO 이후 변동-57.28%최근 뉴스 및 업데이트Reported Earnings • Mar 20Full year 2025 earnings released: ₩18,158 loss per share (vs ₩4,918 loss in FY 2024)Full year 2025 results: ₩18,158 loss per share (further deteriorated from ₩4,918 loss in FY 2024). Revenue: ₩165.5b (down 5.1% from FY 2024). Net loss: ₩272.9b (loss widened 269% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.공시 • Feb 06GC Cell Corporation, Annual General Meeting, Mar 24, 2026GC Cell Corporation, Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South KoreaNew Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Earnings have declined by 62% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).분석 기사 • Nov 05GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The IndustryThe GC Cell Corporation ( KOSDAQ:144510 ) share price has done very well over the last month, posting an excellent gain...분석 기사 • Oct 31GC Cell (KOSDAQ:144510) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Apr 09Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% PlummetUnfortunately for some shareholders, the GC Cell Corporation ( KOSDAQ:144510 ) share price has dived 26% in the last...더 많은 업데이트 보기Recent updatesReported Earnings • Mar 20Full year 2025 earnings released: ₩18,158 loss per share (vs ₩4,918 loss in FY 2024)Full year 2025 results: ₩18,158 loss per share (further deteriorated from ₩4,918 loss in FY 2024). Revenue: ₩165.5b (down 5.1% from FY 2024). Net loss: ₩272.9b (loss widened 269% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.공시 • Feb 06GC Cell Corporation, Annual General Meeting, Mar 24, 2026GC Cell Corporation, Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South KoreaNew Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Earnings have declined by 62% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).분석 기사 • Nov 05GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The IndustryThe GC Cell Corporation ( KOSDAQ:144510 ) share price has done very well over the last month, posting an excellent gain...분석 기사 • Oct 31GC Cell (KOSDAQ:144510) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Apr 09Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% PlummetUnfortunately for some shareholders, the GC Cell Corporation ( KOSDAQ:144510 ) share price has dived 26% in the last...Reported Earnings • Mar 21Full year 2024 earnings released: ₩4,918 loss per share (vs ₩12.00 loss in FY 2023)Full year 2024 results: ₩4,918 loss per share (further deteriorated from ₩12.00 loss in FY 2023). Revenue: ₩174.5b (down 7.0% from FY 2023). Net loss: ₩73.9b (loss widened ₩73.7b from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.공시 • Mar 13GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, A Promising T-Cell Lymphoma CD5 CAR-NK TherapyGC Cell announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB-205), a novel CD5 CAR-NK cell therapy. This "first patient dosing" marks a critical milestone in the company's collaboration with its ex-APAC partner Artiva Biotherapeutics, as company advance the development of this innovative treatment targeting relapsed or refractory NK and T-cell malignancies. With GCC2005, GC Cell is striving to fulfill a significant unmet need in oncology. T-cell lymphomas, which often arise in extranodal lymphoid tissues, are highly aggressive and generally exhibit a poorer prognosis than their B-cell counterparts with limited treatment options. Aimed at expanding possibilities for NK-cell therapies, GCC2005 is an allogeneic cell therapy product manufactured using umbilical cord blood–derived NK cells. Engineered to target the CD5 marker—which is highly expressed on T-cell lymphomas—GCC2005 co-expresses a chimeric antigen receptor (CAR) alongside interleukin-15 (IL-15). This dual expression is designed to enhance the persistence and anti-tumor efficacy of NK cells—effectively addressing a common limitation of conventional NK-cell therapies. The ongoing Phase 1 trial (ClinicalTrials.gov Identifier: NCT06699771) will enroll up to approximately 48 patients diagnosed with relapsed or refractory NK and T-cell malignancies. The primary objectives of the study are to evaluate the safety and tolerability of GCC2005, the maximum tolerated dose (MTD), and the recommended Phase 2 dose (RP2D). Preclinical efficacy data presented last year at the American Association for Cancer Research (AACR) and the T Cell Lymphoma Forum (TCLF) highlighted GCC2005's potent ability to kill tumor cells and improve in vivo persistence. These promising results have bolstered expectations that GCC2005 could become a global first-in-class therapeutic option for T-cell lymphoma. In recognition of its innovative potential, GCC2005 has also been selected by a Korea Drug Development Fund program aimed at promoting global market entry and strategic partnerships in drug development.공시 • Feb 12GC Cell Corporation, Annual General Meeting, Mar 25, 2025GC Cell Corporation, Annual General Meeting, Mar 25, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea분석 기사 • Dec 01The Market Doesn't Like What It Sees From GC Cell Corporation's (KOSDAQ:144510) Revenues Yet As Shares Tumble 27%The GC Cell Corporation ( KOSDAQ:144510 ) share price has fared very poorly over the last month, falling by a...분석 기사 • Oct 14Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share PriceGC Cell Corporation's ( KOSDAQ:144510 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...분석 기사 • Sep 08Is GC Cell (KOSDAQ:144510) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Mar 22Full year 2023 earnings released: ₩12.00 loss per share (vs ₩1,767 profit in FY 2022)Full year 2023 results: ₩12.00 loss per share (down from ₩1,767 profit in FY 2022). Revenue: ₩187.5b (down 21% from FY 2022). Net loss: ₩174.0m (down 101% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.공시 • Jan 09GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI PlatformGC Cell announce the approval from both the Australian Human Research Ethics Committee (HREC) and the Korean Ministry of Food and Drug Safety (MFDS) for a Phase 1 Investigational New Drug (IND) trial for its AB-201 cancer treatment, a HER2 targeted chimeric antigen receptor-natural killer (CAR-NK) cell therapy that shows great promise. Additionally, GC Cell is excited to reveal a strategic partnership with Lunit, the medical AI leader, to enhance precision and clinical intelligence of AB-201's efficacy evaluation by applying its advanced AI technology, in addition to traditional Immunohistochemistry (IHC) based assessments. After participating in the US White House's Cancer Moonshot initiative this past October, both accomplishments represent major milestones in GC Cell's efforts to revolutionize immunotherapy-based cancer treatment while harnessing AI and digital transformation to fight cancer. AB-201, a novel CAR-NK cell therapy targeting solid tumors, represents a breakthrough in cancer immunotherapy, capable of killing malignant cells. While existing NK cell treatments typically dissipate within a few weeks, AB-201 has demonstrated persistence for over three months in preclinical studies, highlighting its potential in managing long-term, advanced cancers. A multi-country study, the Phase 1 trial will evaluate safety and efficacy in 48 patients with HER2-overexpressing breast, gastric, and gastroesophageal junction cancers. GC Cell holds exclusive rights to AB-201 in the Asia Pacific region, while ex-Asia-Pacific rights were licensed to Artiva Biotherapeutics Inc. in an exclusive partnership. A recent McKinsey report found that AI has the potential to increase the value of the pharmaceutical R&D industry by six to eleven billion US dollars. Employing the technology, GC Cell anticipates that AI-driven imaging can analyze vast amounts of data with a high degree of precision and consistency while reducing variability by individual interpretation. This leads to a more accurate assessment of HER2 expression levels, which is vital for appropriate treatment decisions. With such quantitative analysis, AI can help standardize the assessment of cancer target expression across different laboratories and geographical locations. This standardization is essential for multicenter clinical trials and for ensuring that patients receive consistent care regardless of where they are treated. It's a pivotal step in GC Cell's journey towards a digital future, aligning with the broader healthcare industry's shift towards technology-enhanced solutions. AB-201 is an allogeneic HER2-targeted chimeric antigen receptor NK (CAR-NK) cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing. A novel, high affinity anti-HER2 antibody converted to scFv structure confers highly specific tumor targeting and is coupled with a unique costimulatory structure and IL-15 expression for enhanced activity and persistence. AB-201 has demonstrated potent anti-tumor activity in multiple preclinical HER2-positive tumor model systems. The underlying NK cell is derived from umbilical cord blood donors preselected for advantageous attributes including the high affinity variant of the CD16 receptor and a KIR-B haplotype. AB-201 cell products maintain high expression of CD16, as well as other activating innate cell tumor engaging receptors, enabling the potential for dual targeting therapeutic approaches via monoclonal antibody combinations. The resulting CAR-NK is manufactured at very large scale and cryopreserved in infusion-ready media to enable repeat clinical administrations in the outpatient setting. GC Cell holds exclusive rights to AB-201 in the Asia-Pacific region, while ex-Asia-Pacific rights were licensed to Artiva Biotherapeutics Inc. in an exclusive partnership. The U.S. Food and Drug Administration previously cleared Artiva's investigational new drug (IND) application for AB-201 in 2022.Upcoming Dividend • Dec 20Upcoming dividend of ₩350 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.7%).New Risk • Jul 07New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. The company is paying a dividend despite being loss-making. Dividend yield: 1.0% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,767 (vs ₩2,785 in FY 2021)Full year 2022 results: EPS: ₩1,767 (down from ₩2,785 in FY 2021). Revenue: ₩236.1b (up 40% from FY 2021). Net income: ₩26.5b (down 16% from FY 2021). Profit margin: 11% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩70,000, the stock trades at a trailing P/E ratio of 20.6x. Average forward P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 152% over the past three years.Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩74,000, the stock trades at a trailing P/E ratio of 75.9x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 68% over the past three years.Upcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 31 March 2022. Payout ratio is a comfortable 6.9% and this is well supported by cash flows. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).분석 기사 • Mar 19We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are ConservativeWhen companies post strong earnings, the stock generally performs well, just like Green Cross Lab Cell Corporation's...Reported Earnings • Mar 18Full year 2020 earnings released: EPS ₩394 (vs ₩216 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩85.6b (up 48% from FY 2019). Net income: ₩4.16b (up ₩6.44b from FY 2019). Profit margin: 4.9% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.분석 기사 • Feb 22We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...공시 • Feb 10Green Cross Lab Cell Corporation, Annual General Meeting, Mar 24, 2021Green Cross Lab Cell Corporation, Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Jan 27New 90-day high: ₩124,500The company is up 160% from its price of ₩47,850 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period.분석 기사 • Jan 18Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...Is New 90 Day High Low • Dec 22New 90-day high: ₩86,000The company is up 73% from its price of ₩49,800 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 14% over the same period.Upcoming Dividend • Dec 22Upcoming Dividend of ₩25.00 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of December. The trailing yield of 0.03% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.3%).분석 기사 • Dec 14Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...Is New 90 Day High Low • Nov 23New 90-day high: ₩59,100The company is up 4.0% from its price of ₩57,000 on 25 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: ₩45,550The company is down 15% from its price of ₩53,800 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: ₩49,800The company is down 13% from its price of ₩57,200 on 25 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.주주 수익률A144510KR BiotechsKR 시장7D1.5%5.2%6.7%1Y1.2%29.1%181.2%전체 주주 수익률 보기수익률 대 산업: A144510은 지난 1년 동안 29.1%의 수익을 기록한 KR Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: A144510은 지난 1년 동안 181.2%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A144510's price volatile compared to industry and market?A144510 volatilityA144510 Average Weekly Movement9.6%Biotechs Industry Average Movement11.6%Market Average Movement9.4%10% most volatile stocks in KR Market16.6%10% least volatile stocks in KR Market4.9%안정적인 주가: A144510는 지난 3개월 동안 KR 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: A144510의 주간 변동성(10%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트2011698Jai-Wang Kimwww.gccell.comGC녹십자는 세포치료제를 개발하는 회사입니다. 또한 세포 은행, 샘플 검사, 임상 시험 및 바이오 물류 서비스를 제공합니다. 주요 제품은 이뮨셀-엘씨입니다.더 보기GC Cell Corporation 기초 지표 요약GC Cell의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A144510 기초 통계시가총액₩308.81b순이익 (TTM)-₩272.86b매출 (TTM)₩165.52b1.9x주가매출비율(P/S)-1.1x주가수익비율(P/E)A144510는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A144510 손익계산서 (TTM)매출₩165.52b매출원가₩136.55b총이익₩28.97b기타 비용₩301.83b순이익-₩272.86b최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-18.16k총이익률17.50%순이익률-164.85%부채/자본 비율27.1%A144510의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 20:14종가2026/05/26 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스GC Cell Corporation는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jinhee KwakEugene Investment & Securities Co Ltd.Seung-Ho LeeNH Investment & Securities Co., Ltd.
Reported Earnings • Mar 20Full year 2025 earnings released: ₩18,158 loss per share (vs ₩4,918 loss in FY 2024)Full year 2025 results: ₩18,158 loss per share (further deteriorated from ₩4,918 loss in FY 2024). Revenue: ₩165.5b (down 5.1% from FY 2024). Net loss: ₩272.9b (loss widened 269% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
공시 • Feb 06GC Cell Corporation, Annual General Meeting, Mar 24, 2026GC Cell Corporation, Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Earnings have declined by 62% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
분석 기사 • Nov 05GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The IndustryThe GC Cell Corporation ( KOSDAQ:144510 ) share price has done very well over the last month, posting an excellent gain...
분석 기사 • Oct 31GC Cell (KOSDAQ:144510) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Apr 09Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% PlummetUnfortunately for some shareholders, the GC Cell Corporation ( KOSDAQ:144510 ) share price has dived 26% in the last...
Reported Earnings • Mar 20Full year 2025 earnings released: ₩18,158 loss per share (vs ₩4,918 loss in FY 2024)Full year 2025 results: ₩18,158 loss per share (further deteriorated from ₩4,918 loss in FY 2024). Revenue: ₩165.5b (down 5.1% from FY 2024). Net loss: ₩272.9b (loss widened 269% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
공시 • Feb 06GC Cell Corporation, Annual General Meeting, Mar 24, 2026GC Cell Corporation, Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩6.7b free cash flow). Earnings have declined by 62% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
분석 기사 • Nov 05GC Cell Corporation (KOSDAQ:144510) Stock Catapults 29% Though Its Price And Business Still Lag The IndustryThe GC Cell Corporation ( KOSDAQ:144510 ) share price has done very well over the last month, posting an excellent gain...
분석 기사 • Oct 31GC Cell (KOSDAQ:144510) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Apr 09Benign Growth For GC Cell Corporation (KOSDAQ:144510) Underpins Stock's 26% PlummetUnfortunately for some shareholders, the GC Cell Corporation ( KOSDAQ:144510 ) share price has dived 26% in the last...
Reported Earnings • Mar 21Full year 2024 earnings released: ₩4,918 loss per share (vs ₩12.00 loss in FY 2023)Full year 2024 results: ₩4,918 loss per share (further deteriorated from ₩12.00 loss in FY 2023). Revenue: ₩174.5b (down 7.0% from FY 2023). Net loss: ₩73.9b (loss widened ₩73.7b from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.
공시 • Mar 13GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, A Promising T-Cell Lymphoma CD5 CAR-NK TherapyGC Cell announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB-205), a novel CD5 CAR-NK cell therapy. This "first patient dosing" marks a critical milestone in the company's collaboration with its ex-APAC partner Artiva Biotherapeutics, as company advance the development of this innovative treatment targeting relapsed or refractory NK and T-cell malignancies. With GCC2005, GC Cell is striving to fulfill a significant unmet need in oncology. T-cell lymphomas, which often arise in extranodal lymphoid tissues, are highly aggressive and generally exhibit a poorer prognosis than their B-cell counterparts with limited treatment options. Aimed at expanding possibilities for NK-cell therapies, GCC2005 is an allogeneic cell therapy product manufactured using umbilical cord blood–derived NK cells. Engineered to target the CD5 marker—which is highly expressed on T-cell lymphomas—GCC2005 co-expresses a chimeric antigen receptor (CAR) alongside interleukin-15 (IL-15). This dual expression is designed to enhance the persistence and anti-tumor efficacy of NK cells—effectively addressing a common limitation of conventional NK-cell therapies. The ongoing Phase 1 trial (ClinicalTrials.gov Identifier: NCT06699771) will enroll up to approximately 48 patients diagnosed with relapsed or refractory NK and T-cell malignancies. The primary objectives of the study are to evaluate the safety and tolerability of GCC2005, the maximum tolerated dose (MTD), and the recommended Phase 2 dose (RP2D). Preclinical efficacy data presented last year at the American Association for Cancer Research (AACR) and the T Cell Lymphoma Forum (TCLF) highlighted GCC2005's potent ability to kill tumor cells and improve in vivo persistence. These promising results have bolstered expectations that GCC2005 could become a global first-in-class therapeutic option for T-cell lymphoma. In recognition of its innovative potential, GCC2005 has also been selected by a Korea Drug Development Fund program aimed at promoting global market entry and strategic partnerships in drug development.
공시 • Feb 12GC Cell Corporation, Annual General Meeting, Mar 25, 2025GC Cell Corporation, Annual General Meeting, Mar 25, 2025, at 09:01 Tokyo Standard Time. Location: auditorium, 107, ihyeon-ro 30beon-gil, giheung-gu, gyeonggi-do, yongin South Korea
분석 기사 • Dec 01The Market Doesn't Like What It Sees From GC Cell Corporation's (KOSDAQ:144510) Revenues Yet As Shares Tumble 27%The GC Cell Corporation ( KOSDAQ:144510 ) share price has fared very poorly over the last month, falling by a...
분석 기사 • Oct 14Revenues Working Against GC Cell Corporation's (KOSDAQ:144510) Share PriceGC Cell Corporation's ( KOSDAQ:144510 ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy...
분석 기사 • Sep 08Is GC Cell (KOSDAQ:144510) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Mar 22Full year 2023 earnings released: ₩12.00 loss per share (vs ₩1,767 profit in FY 2022)Full year 2023 results: ₩12.00 loss per share (down from ₩1,767 profit in FY 2022). Revenue: ₩187.5b (down 21% from FY 2022). Net loss: ₩174.0m (down 101% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings.
공시 • Jan 09GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI PlatformGC Cell announce the approval from both the Australian Human Research Ethics Committee (HREC) and the Korean Ministry of Food and Drug Safety (MFDS) for a Phase 1 Investigational New Drug (IND) trial for its AB-201 cancer treatment, a HER2 targeted chimeric antigen receptor-natural killer (CAR-NK) cell therapy that shows great promise. Additionally, GC Cell is excited to reveal a strategic partnership with Lunit, the medical AI leader, to enhance precision and clinical intelligence of AB-201's efficacy evaluation by applying its advanced AI technology, in addition to traditional Immunohistochemistry (IHC) based assessments. After participating in the US White House's Cancer Moonshot initiative this past October, both accomplishments represent major milestones in GC Cell's efforts to revolutionize immunotherapy-based cancer treatment while harnessing AI and digital transformation to fight cancer. AB-201, a novel CAR-NK cell therapy targeting solid tumors, represents a breakthrough in cancer immunotherapy, capable of killing malignant cells. While existing NK cell treatments typically dissipate within a few weeks, AB-201 has demonstrated persistence for over three months in preclinical studies, highlighting its potential in managing long-term, advanced cancers. A multi-country study, the Phase 1 trial will evaluate safety and efficacy in 48 patients with HER2-overexpressing breast, gastric, and gastroesophageal junction cancers. GC Cell holds exclusive rights to AB-201 in the Asia Pacific region, while ex-Asia-Pacific rights were licensed to Artiva Biotherapeutics Inc. in an exclusive partnership. A recent McKinsey report found that AI has the potential to increase the value of the pharmaceutical R&D industry by six to eleven billion US dollars. Employing the technology, GC Cell anticipates that AI-driven imaging can analyze vast amounts of data with a high degree of precision and consistency while reducing variability by individual interpretation. This leads to a more accurate assessment of HER2 expression levels, which is vital for appropriate treatment decisions. With such quantitative analysis, AI can help standardize the assessment of cancer target expression across different laboratories and geographical locations. This standardization is essential for multicenter clinical trials and for ensuring that patients receive consistent care regardless of where they are treated. It's a pivotal step in GC Cell's journey towards a digital future, aligning with the broader healthcare industry's shift towards technology-enhanced solutions. AB-201 is an allogeneic HER2-targeted chimeric antigen receptor NK (CAR-NK) cell therapy for the treatment of solid tumors in the outpatient setting with the option for repeat dosing. A novel, high affinity anti-HER2 antibody converted to scFv structure confers highly specific tumor targeting and is coupled with a unique costimulatory structure and IL-15 expression for enhanced activity and persistence. AB-201 has demonstrated potent anti-tumor activity in multiple preclinical HER2-positive tumor model systems. The underlying NK cell is derived from umbilical cord blood donors preselected for advantageous attributes including the high affinity variant of the CD16 receptor and a KIR-B haplotype. AB-201 cell products maintain high expression of CD16, as well as other activating innate cell tumor engaging receptors, enabling the potential for dual targeting therapeutic approaches via monoclonal antibody combinations. The resulting CAR-NK is manufactured at very large scale and cryopreserved in infusion-ready media to enable repeat clinical administrations in the outpatient setting. GC Cell holds exclusive rights to AB-201 in the Asia-Pacific region, while ex-Asia-Pacific rights were licensed to Artiva Biotherapeutics Inc. in an exclusive partnership. The U.S. Food and Drug Administration previously cleared Artiva's investigational new drug (IND) application for AB-201 in 2022.
Upcoming Dividend • Dec 20Upcoming dividend of ₩350 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.7%).
New Risk • Jul 07New minor risk - Dividend sustainabilityThe dividend is not well covered by earnings. The company is paying a dividend despite being loss-making. Dividend yield: 1.0% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: ₩1,767 (vs ₩2,785 in FY 2021)Full year 2022 results: EPS: ₩1,767 (down from ₩2,785 in FY 2021). Revenue: ₩236.1b (up 40% from FY 2021). Net income: ₩26.5b (down 16% from FY 2021). Profit margin: 11% (down from 19% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩70,000, the stock trades at a trailing P/E ratio of 20.6x. Average forward P/E is 27x in the Biotechs industry in South Korea. Total returns to shareholders of 152% over the past three years.
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₩74,000, the stock trades at a trailing P/E ratio of 75.9x. Average trailing P/E is 34x in the Biotechs industry in South Korea. Total returns to shareholders of 68% over the past three years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 31 March 2022. Payout ratio is a comfortable 6.9% and this is well supported by cash flows. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%).
분석 기사 • Mar 19We Think Green Cross Lab Cell's (KOSDAQ:144510) Robust Earnings Are ConservativeWhen companies post strong earnings, the stock generally performs well, just like Green Cross Lab Cell Corporation's...
Reported Earnings • Mar 18Full year 2020 earnings released: EPS ₩394 (vs ₩216 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩85.6b (up 48% from FY 2019). Net income: ₩4.16b (up ₩6.44b from FY 2019). Profit margin: 4.9% (up from net loss in FY 2019). The move to profitability was driven by higher revenue.
분석 기사 • Feb 22We Think Green Cross Lab Cell (KOSDAQ:144510) Can Stay On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
공시 • Feb 10Green Cross Lab Cell Corporation, Annual General Meeting, Mar 24, 2021Green Cross Lab Cell Corporation, Annual General Meeting, Mar 24, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Jan 27New 90-day high: ₩124,500The company is up 160% from its price of ₩47,850 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 21% over the same period.
분석 기사 • Jan 18Can Green Cross Lab Cell Corporation (KOSDAQ:144510) Improve Its Returns?Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Is New 90 Day High Low • Dec 22New 90-day high: ₩86,000The company is up 73% from its price of ₩49,800 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 14% over the same period.
Upcoming Dividend • Dec 22Upcoming Dividend of ₩25.00 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of December. The trailing yield of 0.03% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.3%).
분석 기사 • Dec 14Can You Imagine How Jubilant Green Cross Lab Cell's (KOSDAQ:144510) Shareholders Feel About Its 139% Share Price Gain?Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
Is New 90 Day High Low • Nov 23New 90-day high: ₩59,100The company is up 4.0% from its price of ₩57,000 on 25 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: ₩45,550The company is down 15% from its price of ₩53,800 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: ₩49,800The company is down 13% from its price of ₩57,200 on 25 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
